Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) FCF Margin (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of FCF Margin readings, the most recent being 63.62% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 8702.0% to 63.62% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.31%, a 11803.0% increase, with the full-year FY2025 number at 29.5%, up 9523.0% from a year prior.
  • FCF Margin hit 63.62% in Q4 2025 for Enanta Pharmaceuticals, down from 33.67% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 149.57% in Q2 2025 to a low of 181.45% in Q2 2023.
  • Median FCF Margin over the past 5 years was 112.99% (2025), compared with a mean of 96.29%.
  • Biggest five-year swings in FCF Margin: plummeted -11759bps in 2022 and later soared 26819bps in 2025.
  • Enanta Pharmaceuticals' FCF Margin stood at 48.17% in 2021, then plummeted by -242bps to 164.5% in 2022, then grew by 13bps to 143.17% in 2023, then fell by -5bps to 150.63% in 2024, then surged by 58bps to 63.62% in 2025.
  • The last three reported values for FCF Margin were 63.62% (Q4 2025), 33.67% (Q3 2025), and 149.57% (Q2 2025) per Business Quant data.